zurück

Delamanid (revocation of exemption: pulmonary multi-drug resistant tuberculosis, patients ≥ 10 kg)

Subject:

  • Active Substance: Delamanid
  • Name: Deltyba®
  • Therapeutic area: Tuberculosis
  • Pharmaceutical company: Otsuka Novel Products GmbH

Time table:

  • Start: 15.11.2021
  • Final decision by G-BA: 05.05.2022

Final decision:

  • Pediatric patients weighing 10 kg or more: Hint for a non-quantifiable additional benefit (orphan drug)
  • Adult patients: Hint for a non-quantifiable additional benefit (orphan drug)